The combination of clofarabine and cytarabine in pediatric relapsed acute lymphoblastic leukemia: A case report

Pooja Gidwani, K. H. Ramesh, Yingxian Liu, Edward Anders Kolb

Research output: Contribution to journalArticle

11 Scopus citations

Abstract

Background: Despite significant advances in treatment and survival rates in pediatric acute leukemias, relapse remains a common reason for treatment failure. Survival following relapse is dismal for most patients. Clofarabine, a purine nucleoside analog, has recently been approved for use in relapsed and refractory pediatric acute lymphoblastic leukemia. Clofarabine and cytarabine together may be synergistic and have been used safely in adult leukemia patients. Case Report: We describe the administration of this combination to a 9-year-old boy with multiple relapsed T-cell acute lymphoblastic leukemia who failed to achieve remission after the third attempt. He achieved complete morphologic and cytogenetic remission with 1 cycle of this combination. Conclusion: This case is the first report of successful remission induction in a multiple relapsed pediatric leukemia patient using the clofarabine and cytarabine combination. Although it is a single case, it highlights the need for further studies to assess safety and efficacy of this combination in pediatric patients.

Original languageEnglish (US)
Pages (from-to)120-124
Number of pages5
JournalChemotherapy
Volume54
Issue number2
DOIs
StatePublished - Mar 1 2008

Keywords

  • Acute lymphoblastic leukemia
  • Chemotherapy
  • Pediatric acute leukemia

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Drug Discovery
  • Pharmacology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'The combination of clofarabine and cytarabine in pediatric relapsed acute lymphoblastic leukemia: A case report'. Together they form a unique fingerprint.

  • Cite this